Hyloris Pharmaceuticals has reported a slight rise in its total revenue as part of its full year results for 2024, marking a close to a particularly tumultuous period for the Belgian value-added medicines specialist that has moved closer to profit.
For the whole of the 2024 financial year, Hyloris reported growth in its total revenue and other operating income to...